All In Biotech

Free tool

FAERS Monitor: Duavee

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022247 or its brand name (Duavee, Bazedoxifene Acetate, Estrogens, Conjugated). Reports on generic versions are filed under their own applications.

Reports

938

Serious

207

22% of reports

Hospitalization

34

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective141
  • hot flush78
  • nausea42
  • muscle spasms41
  • off label use39
  • weight increased35
  • feeling abnormal33
  • headache33
  • dizziness31
  • insomnia31
  • pain31
  • therapeutic response unexpected25
  • arthralgia24
  • pain in extremity23
  • drug effect incomplete22

Reports by year received

View as table
YearReports
2014117
2015260
2016101
201772
201858
201958
2020159
202123
202213
202320
202429
202520
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,221 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hot flushSignal7823.218.81,641
drug effect incompleteSignal2213.69.0244
therapeutic response unexpectedSignal2512.58.5254
muscle spasmsSignal415.03.7129
weight increasedSignal353.52.561
feeling abnormalSignal333.12.245
insomniaSignal312.61.830
drug ineffectiveSignal1412.42.1121
pain in extremity231.81.27
dizziness311.41.03
arthralgia241.30.91
nausea421.20.91
headache331.20.81
pain311.10.80
off label use391.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.